20-F: COSCIENS Biopharma Shifts Focus, Exits Biopharma Business

COSCIENS Biopharma Inc. reported a significant net loss for 2025, driven by declining revenues and strategic restructuring, including the wind-down of its biopharmaceutical segment and German subsidiaries.

Summary

• COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) is a life science company focused on natural, plant-based active ingredients and proprietary manufacturing technologies.
• The company reported a consolidated net loss of $10.4 million for the year ended December 31, 2025, compared to $15.3 million in 2024.
• Total revenue for 2025 was $7.5 million, a decrease of 22% from $9.6 million in 2024.
• Active ingredients revenue decreased by 17% to $7.0 million in 2025 from $8.5 million in 2024, primarily due to timing of shipments.
• Pharmaceutical revenue decreased by 58% to $0.5 million in 2025 from $1.1 million in 2024, mainly due to recognized breakage revenue in 2024 following unexpected pediatric trial results.
• Gross profit for 2025 was $2.6 million, down 44% from $4.7 million in 2024, impacted by lower revenues and production overruns in the active ingredients business.
• Research and development expenses significantly decreased by 64% to $3.0 million in 2025 from $8.3 million in 2024, largely due to reduced spending on the DETECT trial and avenanthramides study, and prior year de-recognition of investment tax credits.
• Selling, general and administrative expenses decreased by 4% to $10.1 million in 2025 from $10.4 million in 2024, reflecting cost-cutting measures and downsizing of German office space, partially offset by severance and legal fees.
• The company recognized impairment losses of $240,000 on property and equipment in 2025, related to underutilized Ethanol Recovery System (ERS) and HVAC system.
• A write-down of inventory of $76,000 was recorded in 2025, primarily due to the decision to suspend operations for the JuventeDC cosmeceutical product line.
• Cash used in operating activities was $8.5 million in 2025, an improvement from $14.6 million in 2024.
• As of December 31, 2025, cash and cash equivalents stood at $7.3 million, down from $16.4 million in 2024.
• The company announced a strategic decision on March 5, 2026, to cease funding its German biopharmaceutical subsidiaries (Aeterna Zentaris GmbH and Zentaris IVF GmbH), leading to insolvency filings on March 23, 2026.
• This wind-down is expected to generate approximately $1.9 million in annualized cost savings by eliminating ongoing operating losses and reducing administrative costs.
• The company anticipates surrendering its rights to Macrilen (macimorelin) as a result of the insolvency process.
• Management concluded that material weaknesses in internal control over financial reporting identified in 2024 were remediated as of December 31, 2025.
• The company voluntarily delisted from NASDAQ effective September 5, 2025, and intends to suspend its U.S. public reporting obligations under the Exchange Act in 2026, while remaining listed on the TSX and OTC Market.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, primarily due to continued significant losses, declining revenues, and the complete exit from the biopharmaceutical segment after a major clinical trial failure. While cost-cutting and remediation of internal controls are positive, the overall financial health and strategic setbacks warrant a low score.

Positives

• Net loss decreased to $10.4 million in 2025 from $15.3 million in 2024, representing a $4.9 million improvement.
• Cash used in operating activities decreased by $6.1 million in 2025 compared to 2024, indicating improved operational cash management.
• Research and development expenses significantly decreased by 64% in 2025, reflecting cost optimization efforts.
• Selling, general and administrative expenses decreased by 4% in 2025, driven by cost-cutting measures and restructuring.
• Remediation of previously identified material weaknesses in internal control over financial reporting was completed as of December 31, 2025, enhancing financial reporting reliability.
• The strategic decision to wind down the biopharmaceutical business is expected to generate approximately $1.9 million in annualized cost savings.
• Construction and technical validation of PGX Technology scale-up facilities in Edmonton and Austria are complete, advancing commercialization efforts for this proprietary technology.

Negatives

• The company reported a consolidated net loss of $10.4 million for the year ended December 31, 2025, and an accumulated deficit of $20.5 million, raising substantial doubt about its ability to continue as a going concern.
• Total revenue decreased by 22% to $7.5 million in 2025, primarily due to declines in both active ingredients and pharmaceutical segments.
• Gross profit decreased by 44% in 2025, impacted by lower revenues and production overruns.
• Cash and cash equivalents decreased significantly to $7.3 million at year-end 2025 from $16.4 million in 2024.
• The biopharmaceutical business, including Macrilen, has historically operated at a loss, leading to the strategic decision to cease funding and file for insolvency of German subsidiaries.
• The Phase 3 DETECT trial for Macrilen failed to meet its primary endpoints, representing a significant setback for pediatric approval in the U.S.
• The company is heavily dependent on one distribution partner, Symrise AG, for over 84% of its revenues, posing a significant concentration risk.
• Impairment losses of $240,000 on property and equipment and a $76,000 write-down of inventory were recorded in 2025.

Risks

• Revenues and expenses may fluctuate significantly, potentially leading to failure to meet financial expectations and a decline in share price.
• Substantial doubt exists about the company's ability to continue as a going concern due to historical operating losses and negative cash flows.
• Heavy dependence on one distribution partner (Symrise AG) for over 84% of revenues creates significant risk if demand declines or the agreement is not extended beyond December 31, 2026.
• Inability to generate significant revenues if products do not gain market acceptance or if acceptable prices/reimbursement are not obtained.
• Intense competition in cosmeceutical, nutraceutical, and biopharmaceutical markets could render products non-competitive.
• Share price volatility may result from factors outside of the company's control, including market conditions and company-specific announcements.
• Delisting of Common Shares from the TSX could impact market price and liquidity.
• Dependence on a stable and consistent supply of high-quality ingredients and raw materials, which are subject to adverse conditions like weather and natural disasters.
• Failure of third-party manufacturers to perform satisfactorily may lead to supply shortfalls.
• Uncertainty regarding successful commercialization of PGX Technology and finding commercial partners.
• Requirement for significant additional financing, with no assurance of access to sufficient capital on acceptable terms, potentially leading to dilution or debt restrictions.
• Economic effects of public health crises could adversely affect operations or share price.
• Uncertainty regarding the ultimate outcome of insolvency proceedings for German subsidiaries, including timing, court supervision, and disposition of intellectual property and assets related to Macrilen.
• Net operating losses may be limited under U.S. tax laws (Section 382 of the Internal Revenue Code) due to past or future ownership changes.
• Potential classification as a Passive Foreign Investment Company (PFIC) could result in adverse tax consequences for U.S. investors.
• Investments in the company's industries are generally considered speculative.
• Imposition of duties, tariffs, and other trade barriers could materially adversely affect business, financial condition, and results of operations.
• Expending limited resources on a particular product or indication may lead to failure to capitalize on other potentially more successful opportunities.
• Inability to obtain adequate protection for products through intellectual property and trademark registrations, or infringement of others' IP rights.
• Failure to comply with current Good Manufacturing Practice (GMP) regulations by the company or its contract manufacturers.
• Risk of product liability claims for which adequate insurance coverage may not be available.
• As a holding company, claims of creditors of subsidiaries will generally have priority over the company's claims and those of its creditors and shareholders.
• Difficulty for U.S. investors to obtain and enforce judgments against the company due to Canadian incorporation and corporate structure.
• Inability to maintain an effective system of internal controls over financial reporting, potentially leading to inaccurate financial results or fraud.
• Subject to environmental laws and potential remediation obligations that could have a material adverse effect.
• Losses associated with foreign currency fluctuations.
• Legislative actions, new accounting pronouncements, and higher insurance costs may adversely impact future financial position or results.
• Data security breaches and other cybersecurity risks may disrupt operations and adversely affect operating results.
• Future issuances of securities and hedging activities may depress the trading price of Common Shares.
• Blank check preferred share provisions in articles of incorporation could delay or impede an acquisition.
• Business could be negatively affected by actions of activist shareholders.
• Intense competition for skilled personnel, and the loss of key personnel or inability to attract additional personnel could impair operations.
• Loss of foreign private issuer status could require compliance with the U.S. domestic reporting regime, incurring additional expenses.

Future Outlook

The company plans to focus on its natural, plant-based active ingredients business, leveraging proprietary manufacturing and extraction technologies. It anticipates significant annualized cost savings of approximately $1.9 million by winding down its biopharmaceutical segment and German subsidiaries. Efforts are accelerating for the development and commercialization of its patented PGX Technology, including engaging potential industry partners. The company intends to suspend its U.S. public reporting obligations under the Exchange Act in 2026 to further reduce costs, while maintaining its TSX and OTC Market listings. Management believes existing cash on hand will be sufficient to fund anticipated operating and capital expenditure requirements for at least the next 12 months and through to 2027.

Management Comments

• Management believes that cash on hand and future cash flows from operations will be adequate to support the company's financial liabilities, though future cash flows are dependent on factors outside its control.
• The company has the ability to scale its research and development activities, capital expenditures and restructure operations, and will do so as necessary, based on cash availability.
• Management is actively evaluating its overall manufacturing process and procurement strategy to identify potential areas for future margin improvement and cost reduction.
• Management concluded that the deficiencies that previously contributed to the material weaknesses in internal control over financial reporting were remediated as of December 31, 2025.

Industry Context

StockSavvy.ai notes that COSCIENS Biopharma's strategic shift away from its loss-making biopharmaceutical segment, particularly after the Macrilen trial setback, aligns with a broader industry trend of companies rationalizing portfolios to focus on core profitable areas. The emphasis on natural, plant-based active ingredients and proprietary extraction technologies like PGX positions the company in the growing nutraceutical and cosmeceutical markets, which are less capital-intensive and have different regulatory pathways compared to pharmaceuticals. The high dependence on a single distributor (Symrise AG) is a notable concentration risk, common in specialized ingredient supply chains, but the company's efforts to diversify its customer base are crucial for long-term stability. The move to reduce U.S. reporting obligations is a cost-saving measure often seen in smaller companies seeking to optimize administrative overhead.

Comparison to Industry Standards

• The company's gross margin of 35% in 2025 for its active ingredients business is within the typical range for specialty chemical and ingredient suppliers, though lower than the 49% in 2024, indicating pressure on profitability.
• The significant reduction in R&D expenses from $8.3 million in 2024 to $3.0 million in 2025 is a stark contrast to the typical R&D intensity of biopharmaceutical companies, reflecting the strategic pivot away from drug development.
• The reliance on a single customer for 84% of total revenue is significantly higher than industry averages for diversified ingredient suppliers, where customer concentration typically ranges from 10-30% for top clients, exposing the company to substantial customer-specific risk.
• The accumulated deficit of $20.5 million and negative operating cash flow of $8.5 million in 2025 are indicative of a company in a challenging financial position, common for early-stage biopharma or specialty ingredient firms, but raising going concern doubts.

Management Changes

Corporate Governance

Legal Proceedings

• German subsidiaries (Aeterna Zentaris GmbH and Zentaris IVF GmbH) filed insolvency petitions in a German court on March 23, 2026.
• The company may, from time to time, be a party to litigation and subject to claims incidental to its business, with potential for significant legal fees and damages.

Related Party Transactions

• During 2025, the company made no payments for research and development expenditures to Angiogenesis Foundation, for which a former Director was the CEO (compared to $50,000 in 2024 and $201,000 in 2023).

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future equity raises and uncertainty regarding the company's ability to continue as a going concern. The strategic shift and exit from biopharma may impact long-term growth prospects, but cost savings could improve financial stability. The delisting from NASDAQ and potential suspension of SEC reporting may affect liquidity and transparency for U.S. investors.
• **Employees:** Experienced restructuring, including reduced headcount and changes in leadership. German employees of the biopharmaceutical subsidiaries are directly impacted by the insolvency filings. Retention of skilled personnel remains a challenge due to intense competition and compensation limitations.
• **Customers:** The active ingredients business relies heavily on one distribution partner (Symrise AG), making customers vulnerable to changes in this relationship. The wind-down of Macrilen impacts patients and healthcare providers who relied on this diagnostic test.
• **Suppliers:** The company's dependence on a stable supply of raw materials means suppliers face risks related to demand fluctuations and potential interruptions.
• **Creditors:** Claims of creditors of the German subsidiaries will have priority over the parent company's claims in the insolvency proceedings. The company's overall financial liabilities and going concern doubts pose risks to creditors.

Next Steps

• Accelerate development and commercialization efforts for patented PGX Technology.
• Engage potential industry partners for PGX Technology licensing and integration.
• File a Rule 13e-3 Transaction Statement on Schedule 13E-3 with the SEC in connection with a proposed transaction to suspend U.S. public reporting obligations.
• Continue to meet public reporting obligations as a reporting issuer under applicable Canadian securities laws.
• Actively search for a buyer for the HVAC system (classified as held for sale).
• Monitor potential direct and indirect impacts of tariffs, retaliatory tariffs, or other trade protectionist measures.

Key Dates

Recommendation

The company faces substantial doubt about its ability to continue as a going concern, evidenced by persistent net losses, negative operating cash flows, and a significant decline in cash reserves. The strategic exit from the biopharmaceutical segment, including the surrender of Macrilen rights after a failed Phase 3 trial, eliminates a key growth driver and indicates a failure in a major R&D investment. While cost-cutting measures and improved internal controls are positive, the severe revenue decline, high customer concentration risk, and the need for significant future capital raises (with associated dilution risk) present a highly speculative investment profile. A seasoned investor would likely view these factors as strong indicators to exit the position due to fundamental business challenges and high uncertainty.

Keywords

Biopharma, Active Ingredients, Oat-based products, PGX Technology, Avenanthramides, Macrilen, Insolvency, Cost Savings, SEC Reporting, Financial Results, Research and Development, Corporate Restructuring, Canada Business Corporations Act, Intellectual Property, Risk Management